Wilmington Savings Fund Society FSB Has $636,000 Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Wilmington Savings Fund Society FSB lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 945.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,850 shares of the company’s stock after purchasing an additional 26,091 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Teva Pharmaceutical Industries were worth $636,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. UMB Bank n.a. grew its stake in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares in the last quarter. Smithfield Trust Co lifted its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the period. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $52,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $66,000. Finally, Venturi Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. Institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

TEVA has been the topic of a number of research analyst reports. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of NYSE TEVA opened at $16.82 on Tuesday. The company has a 50 day simple moving average of $20.05 and a 200 day simple moving average of $18.52. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 1 year low of $12.43 and a 1 year high of $22.80. The firm has a market cap of $19.05 billion, a PE ratio of -11.60, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.